car-t – Asia Tab

Novotech和Endpoints展示“中国细胞和基因治疗的演变：通用CAR-T的案例”

July 19, 2022

SYDNEY, Jul 19, 2022 - (亚太商讯 via SEAPRWire.com) - Novotech 是亚太地区领先的生物技术专家 CRO，在美国提供扩展服务，很高兴在中国举办一场关于 CAR-T 治疗的 Endpoints 网络研讨会——当前形势和未来机遇。中国目前占全球 CAR-T 疗法临床开发的 60%。该网络研讨会将涵盖迄今为止的学习成果和未来的机会。涵盖的具体领域包括：- 中国生物技术 CAR-T 治疗研究的现状- 中国CAR-T临床开发：重点关注领域- 与通用 CAR-T 细胞疗法开发相关的潜在机会- 同种异体 CAR-T 细胞疗法的挑战在这里注册： https://webinars.endpts.com/evolution-of-cell-gene-therapy-in-china-the-case-for-universal-car-t/网络研讨会日期：- 2022 年 7 月 19 日- 美国东部时间下午 1:00 - 下午 2:00主持人：- Arsalan Arif，创始人兼出版商端点新闻演讲者：- 生物恒首席医疗官程洁博士- Novotech 中国首席营销官临床开发与监管副总裁 Vivian Gu 博士- Kai Xue博士，中国上海瑞金医院血液科副教授根据全球数据白皮书: 与美国和欧盟相比，亚太地区临床试验的演变5 在过去五年中，在亚太地区、美国和欧盟5 注册了超过 70,000 项新的临床试验。亚太地区是最大的贡献者，超过 50% 的试验其次是美国（29%）和欧盟五国（17%）。亚太地区已成为开展临床试验的首选目的地，因为其患者人数众多、易于遵守法规、开展研究的成本低、高质量标准和顶级临床站点的存在。Novotech首席执行官 John Moller 博士表示：“过去五年对亚太地区生物技术临床研究的关注使该地区成为增长最快的临床试验目的地，中国成为新试验的主要地点，其次是美国。Novotech 在亚太地区以提供全方位服务、高质量的快速临床试验而享有盛誉，现在可以在美国为其生物技术客户提供临床服务，以支持后期的全球研究。Novotech 的服务交付模式是根据生物技术客户的需求量身定制的。我们的本地团队拥有出色的现场和研究人员访问权限，我们的项目管理方法强调解决问题、所有权和灵活性，我们在数据和技术方面的投资确保客户能够实时访问试验绩效。”Novotech 最近被评为全球领先 CRO 中的前 10 名 CRO，并在过去 3 年中签署了 45 份领先的网站合作协议。关于Novotech健康控股Novotech健康控股有限公司（“Novotech”）是亚太地区及美国领先的生物技术专家 CRO。 Novotech 是一家 CRO，拥有综合实验室和 I 期设施，提供药物开发咨询和临床开发服务。它有助于在所有试验阶段和广泛的治疗领域成功进行大约 4,000 项临床试验。Novotech具有明显优势，可以为在亚洲及美国进行临床试验的生物制药客户提供服务。详细信息请访问 https://novotech-cro.com/contact媒体联系人David JamesE: communications@novotech-cro.com澳大利亚: +61 2 8218 2144美国: +1 415 951 3228亚洲: +65 3159 3427 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Novotech and Endpoints Present “Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T”

July 18, 2022

SYDNEY, Jul 18, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, is pleased to present an Endpoints webinar on CAR-T therapy in China - the current landscape and future opportunities. China now represents 60% of clinical development in CAR-T therapy development globally. This webinar will cover learnings to date and future opportunities.Specific areas covered include:- The current landscape for biotech CAR-T therapy research in China- CAR-T clinical development in China: key areas of focus- Potential opportunities related to universal CAR-T cell therapy development- The challenges of allogeneic CAR-T cell therapyRegister here: https://webinars.endpts.com/evolution-of-cell-gene-therapy-in-china-the-case-for-universal-car-t/Webinar Date:- July 19, 2022- 1:00 pm - 2:00 pm EDTModerator:- Arsalan Arif, Founder and Publisher Endpoints News Presenters:- Dr. Jie Cheng, Chief Medical Officer Bioheng- Dr. Vivian Gu, Vice President, Clinical Development & Regulatory, CMO, Novotech China- Dr Kai Xue, Associate Professor, Department of Haematology, Ruijin Hospital, Shanghai, ChinaAccording to Global Data: "Over the last five years more than 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%). The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, lower cost of conducting studies, high-quality standards and the presence of top clinical sites." Novotech CEO Dr. John Moller said: "The Asia-Pacific is the fastest-growing clinical trial destination for biotechs, with China being the leading location for new trials followed by the US. Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, also offers its biotech clients clinical services in the US to support later phase global studies. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years. About Novotech Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)